AI Article Synopsis
- The study investigated the prevalence of nonalcoholic fatty liver disease (NAFLD) in Korean adults, finding that 10% of participants had NAFLD, diagnosed with a fatty liver index (FLI) of 60 or higher.
- Results showed a strong association between higher FLI values and increased risk for hypertension, diabetes, and metabolic syndrome (MetS), with higher FLI groups experiencing significantly worse health outcomes.
- The study concluded that FLI could serve as an effective screening tool for identifying individuals at risk for metabolic disorders, suggesting a cutoff value of 20 for predicting MetS presence.
Article Abstract
Purpose: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, and it is the hepatic manifestation of metabolic syndrome (MetS). We aimed to estimate the prevalence of NAFLD defined by the fatty liver index (FLI), in order to investigate the association between FLI and metabolic disorders and to determine the cutoff value of FLI to screen for MetS.
Subjects And Methods: This study utilized a national representative sample of Korean adults (the Korean National Health and Nutrition Examination Surveys) which was conducted in 2010-2011. A total of 10,107 adults aged 19 years or older were selected. NAFLD was diagnosed on the basis of an increased FLI (≥60) after the exclusion of alcohol or viral liver disease.
Results: NAFLD was identified in 1,134 subjects (age-standardized prevalence, 10.0%). When subjects were categorized into three groups by FLI (<20, 20-59, and ≥60), the higher FLI group showed a higher prevalence of hypertension (49.7% vs 14.4%), diabetes mellitus (DM; 20.4% vs 3.8%), and MetS (74.9% vs 7.4%). FLI was positively associated with age, body mass index, blood pressure, hemoglobin A1c, and homeostasis model assessment of insulin resistance ( for trend <0.001). In the multivariate analysis, the higher FLI group had a significantly higher risk for hypertension (OR =2.92, 95% CI =2.18-3.90, <0.001), DM (OR =4.38, 95% CI =2.96-6.49, <0.001), and MetS (OR =24.85, 95% CI =17.33-35.64, <0.001). However, no increase was observed for cardiovascular disease after adjustment of other risk factors. The cutoff value of the FLI estimated to predict the presence of MetS was 20 (area under the curve 0.849, sensitivity 0.828, and negative predictive value 91.9%).
Conclusion: NAFLD prevalence using FLI is significantly higher in subjects with metabolic disorder including MetS. FLI might be a useful screening tool to detect subjects who may require early management of MetS and who have a high cardiovascular risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353218 | PMC |
| http://dx.doi.org/10.2147/DMSO.S189544 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease.
Hepatology
January 2025
Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.
Background And Aims: Alcohol-related liver disease (ALD) is one of the leading causes of severe liver disease with limited pharmacological treatments for alcohol-related steatohepatitis (ASH). CD44, a glycoprotein mainly expressed in immune cells, has been implicated in multiple inflammatory diseases but has never been studied in the ALD context. We therefore studied its contribution to ASH development in mice and its expression in ALD patients.
View Article and Find Full Text PDFComparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort.
Clin Exp Med
January 2025
Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt.
The diagnostic criteria for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Metabolic Associated Steatotic Liver Disease (MASLD) aim to refine the classification of fatty liver diseases previously grouped under Non-Alcoholic Fatty Liver Disease (NAFLD). This study evaluates the applicability of the MAFLD and MASLD frameworks in NAFLD patients, exploring their clinical utility in identifying high-risk patients. A total of 369 NAFLD patients were assessed using MAFLD and MASLD diagnostic criteria.
View Article and Find Full Text PDFMeta-Analysis of Placebo-Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials.
Aliment Pharmacol Ther
January 2025
Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Background: Dropout is common and affects the statistical power and randomization balance of randomised controlled trials (RCTs).
Aims: To estimate the dropout rate in RCTs of metabolic dysfunction-associated steatohepatitis (MASH) and to examine factors associated with dropout in placebo-treated participants.
Methods: PubMed and Cochrane databases were searched for phase 2-4 MASH RCTs with placebo arms through November 24, 2024.
SWM-008 red mold rice and its components, monascinol and monascin, reduce obesity in a high-fat diet-induced rat model through synergistic modulation of gut microbiota and anti-lipogenesis.
Food Funct
January 2025
Department of Life Science, National Taitung University, Taitung 95092, Taiwan, Republic of China.
This study is the first to explore the effects of the novel yellow pigment monascinol (Msol) from red mold rice (RMR) on reducing body fat and to compare its effects with those of monascin (MS) and ankaflavin (AK). In a high-fat diet-induced rat model, different doses of RMR fermented rice (RL, RM, RH) and purified Msol, MS, and AK were administered over an 8-week period. The results showed that all treatment groups significantly reduced body weight and fat mass.
View Article and Find Full Text PDFNon-alcoholic fatty liver disease (NAFLD) is a chronic condition characterized by hepatic steatosis in the absence of significant alcohol consumption and is increasingly recognized as the hepatic manifestation of metabolic syndrome (MetS). This review aims to explore the molecular mechanisms underlying the interaction between NAFLD, insulin resistance (IR), and MetS, with a focus on identifying therapeutic targets. A comprehensive review of existing literature on NAFLD, IR, and MetS was conducted.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!